The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2022
Filed:
Nov. 10, 2017
Applicant:
Ipsen Biopharm Ltd., Wrexham, GB;
Inventors:
Eliel Bayever, New York, NY (US);
Sarah F. Blanchette, Lynnfield, MA (US);
Jonathan Basil Fitzgerald, Arlington, MA (US);
Daniel F. Gaddy, Cambridge, MA (US);
Bart S. Hendriks, Belmont, MA (US);
Ashish Kalra, Belmont, MA (US);
Helen Lee, Arlington, MA (US);
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/282 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/475 (2006.01); A61K 31/436 (2006.01); A61K 47/20 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 31/282 (2013.01); A61K 31/436 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 47/20 (2013.01); A61K 2300/00 (2013.01);
Abstract
Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.